Medsir

This study tests a combination of two drugs, zongertinib and fulvestrant, in people with advanced breast cancer that is hormone receptor-positive and HER2-negative but has a specific HER2 gene mutation. The goal is to see if the combination shrinks tumors. About 25 adults will ta…

This study tests a new combination of drugs (zanidatamab, tucatinib, and chemotherapy) in people with advanced HER2-positive breast cancer that cannot be removed by surgery or has spread. The goal is to find the safest dose and see if the treatment shrinks tumors. About 24 adults…

This study tests a new drug called bexmarilimab (an antibody) combined with the chemotherapy doxorubicin in people with metastatic soft-tissue sarcoma. The trial has two parts: first, finding the safest dose, then checking if the combination helps slow the cancer. About 278 adult…

This study tests special radioactive drugs that can both find and treat solid tumors that have spread to the brain. Ten adults with advanced breast cancer and active brain metastases will receive a single dose of a diagnostic agent to see if it lights up the brain tumors on a sca…

This study tests whether giving atropine before treatment can prevent diarrhea in people with advanced breast cancer receiving the drug sacituzumab govitecan. About 30 participants will receive atropine alongside their cancer therapy. The goal is to improve treatment tolerance an…

This study will examine stored tumor samples from 244 people diagnosed with biliary tract cancer in the last 15 years. Researchers will measure five specific markers (CLDN18.2, HER2, TROP2, PD-L1, and B7-H4) to see how common they are and how they relate to patient outcomes. The …